Lyme Disease Chronic Reflexive Panel
Navigation Links
Lyme Disease Chronic Reflexive Panel
| Products | Lyme Disease Chronic Reflexive Panel |
| Company | ARUP Laboratories |
| Item | Lyme Disease Chronic Reflexive Panel |
| Features | |
| Description | ARUP Laboratories is a national reference laboratory and a worldwide leader in innovative laboratory research and development. ARUP offers an extensive test menu of highly complex and unique medical tests in clinical and anatomic pathology. Owned by the University of Utah, ARUP Laboratories' clients include more than half of the nation's university teaching hospitals and children's hospitals, major commercial laboratories, military and government facilities, and major clinics. |
| Info | ARUP Laboratories Customer Service: (800) 522-2787 Web site: http://www.aruplab.com |
Related medicine products :
1. Anti-Gliadin IgG & IgA (Ab) EIA Gastrointestinal Markers 027-GD77 Celiac Disease Food Allergy
2. Anti-Gliadin IgG (Ab) EIA Gastrointestinal Markers 027-GD16 Celiac Disease Food Allergy
3. Anti-Gliadin IgA (Ab) EIA Gastrointestinal Markers 027-GD17 Celiac Disease Food Allergy
4. Myoglobin EIA Lipid / Protein Quantification, Cardiovascular 024-IDC-13 Muscle Disease
5. Myoglobin RIA Lipid / Protein Quantification, Cardiovascular 024-IDC-11 Muscle Disease
6. Siemens Webcast: Soarian Disease Management
7. ICD-9-CM International Classification of Diseases, Ninth Revision, Clinical Modification
8. Cochrane Reviews in Peripheral Vascular Diseases
9. Dx/Rx: Valvular Heart Disease
10. Expert Guide to Beating Heart Disease M
11. Cochrane Reviews in Neuromuscular Disease
Breaking Medicine News(10 mins):Health News:IOM report on national vaccine plan 2Health News:IOM report on national vaccine plan 3Health News:Casual Sex Doesn't Cause Emotional Damage: Study 2Health News:Drug Information Association (DIA) Announces New Clinical Safety and Pharmacovigilance Certificate Program 2Health News:Drug Information Association (DIA) Announces New Clinical Safety and Pharmacovigilance Certificate Program 3Health News:Study Finds Possible Explanation for the Link Between Infertility and Breast/Ovarian Cancer Risks 2Health News:Physical Therapist, Money Launderer and Patient Recruiter Plead Guilty in Connection With Multiple Detroit Health Care Fraud Schemes 2Health News:Physical Therapist, Money Launderer and Patient Recruiter Plead Guilty in Connection With Multiple Detroit Health Care Fraud Schemes 3Health News:Physical Therapist, Money Launderer and Patient Recruiter Plead Guilty in Connection With Multiple Detroit Health Care Fraud Schemes 4
[0] IOM report on national vaccine plan[0] Casual Sex Doesn't Cause Emotional Damage: Study[0] Drug Information Association (DIA) Announces New Clinical Safety and Pharmacovigilance Certificate Program [0] Study Finds Possible Explanation for the Link Between Infertility and Breast/Ovarian Cancer Risks[0] Physical Therapist, Money Launderer and Patient Recruiter Plead Guilty in Connection With Multiple Detroit Health Care Fraud Schemes
Other Medicine News:Health News:Eagle Ventures' Subsidiary Hydrate2O Receives '2008 Top Gear of the Year' Award From ShapeYou.com 2Health News:Eagle Ventures' Subsidiary Hydrate2O Receives '2008 Top Gear of the Year' Award From ShapeYou.com 3Health News:Eagle Ventures' Subsidiary Hydrate2O Receives '2008 Top Gear of the Year' Award From ShapeYou.com 4Health News:Osteotech Reports 2008 Second Quarter Diluted Earnings Per Share of $.10 on Revenues of $27.6 Million 2Health News:Osteotech Reports 2008 Second Quarter Diluted Earnings Per Share of $.10 on Revenues of $27.6 Million 3Health News:Osteotech Reports 2008 Second Quarter Diluted Earnings Per Share of $.10 on Revenues of $27.6 Million 4Health News:Osteotech Reports 2008 Second Quarter Diluted Earnings Per Share of $.10 on Revenues of $27.6 Million 5Health News:NeoGenomics Announces Results for the Second Quarter of Fiscal Year 2008 2Health News:NeoGenomics Announces Results for the Second Quarter of Fiscal Year 2008 3Health News:NeoGenomics Announces Results for the Second Quarter of Fiscal Year 2008 4Health News:NeoGenomics Announces Results for the Second Quarter of Fiscal Year 2008 5Health News:NeoGenomics Announces Results for the Second Quarter of Fiscal Year 2008 6Health News:NeoGenomics Announces Results for the Second Quarter of Fiscal Year 2008 7Health News:NeoGenomics Announces Results for the Second Quarter of Fiscal Year 2008 8Health News:New Website Helps Doctors and Dentists Locate Disability Insurance 2Health News:New Website Helps Doctors and Dentists Locate Disability Insurance 3Health News:Healthcare Leaders Focus on Patient-Centered Care at Annual Planetree Conference 2Health News:Healthcare Leaders Focus on Patient-Centered Care at Annual Planetree Conference 3
Eagle Ventures' Subsidiary Hydrate2O Receives '2008 Top Gear of the Year' Award From ShapeYou.comOsteotech Reports 2008 Second Quarter Diluted Earnings Per Share of $.10 on Revenues of $27.6 MillionNeoGenomics Announces Results for the Second Quarter of Fiscal Year 2008New Website Helps Doctors and Dentists Locate Disability InsuranceHealthcare Leaders Focus on Patient-Centered Care at Annual Planetree ConferencePHA Commends House Passage of Tobacco Legislation
Breaking Medicine Technology:Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 2Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 2New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 3New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 4VisEn Launches New OsteoSense 28R 29 800 and VivoTag 28R 29 800 Fluorescence Molecular Imaging Agents 6408 1VisEn Launches New OsteoSense 28R 29 800 and VivoTag 28R 29 800 Fluorescence Molecular Imaging Agents 6408 2VerifyNow 28R 29 System Highlighted in POPular Study Comparing Platelet Reactivity Tests 6404 1VerifyNow 28R 29 System Highlighted in POPular Study Comparing Platelet Reactivity Tests 6404 2Caliper Life Sciences Partners with Prestwick Chemical to Offer Customized Chemistry and Biology Programs for Drug Discovery Research 6400 1Caliper Life Sciences Partners with Prestwick Chemical to Offer Customized Chemistry and Biology Programs for Drug Discovery Research 6400 2Caliper Life Sciences Partners with Prestwick Chemical to Offer Customized Chemistry and Biology Programs for Drug Discovery Research 6400 3
[0] Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug[0] FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology[0] New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |